EVO ICL for High Prescriptions: The Better Choice When LASIK Won’t Work

If you have been told that your prescription is too strong for LASIK, you are not alone, and you are not out of options. Every week in my Newport Beach practice, I evaluate patients who have been turned away from LASIK at other practices because of their high prescriptions. Most of them leave my office with a clear understanding that EVO ICL™ was designed specifically for eyes like theirs, and the procedure will give them the vision they thought they had to live without.

This blog explains why LASIK has a ceiling for high prescriptions, what that ceiling is grounded in clinically, and why EVO ICL is often the strongest answer for patients above it.

What Counts as a “High Prescription”

The threshold at which a refractive surgeon starts to hesitate about LASIK is not a single number. It depends on four things: the strength of your prescription, your corneal thickness, whether your cornea is biomechanically stable enough to safely undergo a corneal refractive procedure (LASIK, PRK, or SMILE), and the overall health of your eye. We use the Pentacam, an advanced imaging device that maps the cornea’s full three-dimensional shape, including the back surface, which is the most sensitive early indicator of corneal weakness. As a general rule, however:

• Below -6.00 D: LASIK is usually straightforward
• -6.00 D to -8.00 D: LASIK is often safe, but corneal thickness becomes a gating factor
• -8.00 D to -10.00 D: A subset of patients are still safe LASIK candidates, but many are not
• Above -10.00 D: LASIK is rarely the right answer; EVO ICL or refractive lens exchange becomes the appropriate procedure

The reason the threshold blurs at higher prescriptions is that LASIK does not have a clean ceiling at any one diopter value. The ceiling is set by the physical anatomy of your specific cornea, combined with two limits that become more pronounced the higher the prescription climbs.

The Tissue Limit: There Is Only So Much That Can Safely Be Removed

LASIK corrects vision by removing corneal tissue with an excimer laser. The higher the prescription, the more tissue must be removed. There is a real biomechanical limit to how thin a cornea can be made before it becomes unstable.

This is where the surgeon’s job becomes a careful calculation. The accepted clinical framework for this assessment is Percent Tissue Altered (PTA), developed and validated by Santhiago, Randleman, and colleagues in a landmark 2014 study published in the American Journal of Ophthalmology. PTA is calculated as the flap thickness plus the laser ablation depth, divided by the total preoperative corneal thickness.

The Santhiago study found that a PTA of 40% or higher was the single most powerful independent predictor of post-LASIK corneal ectasia in eyes with otherwise normal preoperative topography. In the ectasia group, 97% of affected eyes had a PTA of 40% or higher, with an odds ratio of 223 (Santhiago MR, et al. Am J Ophthalmol. 2014;158(1):87-95).

In plain language: of all the factors that can predict whether a LASIK patient will develop ectasia, none is more powerful than PTA. Not corneal thickness alone. Not residual stromal bed. Not age. Not the older Ectasia Risk Scoring System. PTA outperformed all of them combined.

I do not perform LASIK on any patient whose PTA exceeds 40%. Period.

Now extend that math further. At -10.00 D, the laser must remove approximately 140 to 150 microns of tissue. Add the 100-micron flap and the total tissue altered is roughly 240 to 250 microns. On a 550-micron cornea, that is a PTA of 44% to 45%, above the safety threshold. On a 500-micron cornea, it is 48% to 50%. LASIK is no longer a safe option for that patient, regardless of how well the rest of the eye looks.

This is not a marketing claim. It is the physics of the cornea, validated by some of the strongest peer-reviewed evidence in modern refractive surgery, and every responsible refractive surgeon respects it.

The Night Vision Limit: Image Quality Degrades as the Amount of Treatment Increases

The second limit is more subtle, but for patients who do a lot of night driving, it is often the more meaningful one.

When the laser reshapes the cornea, it works within a defined optical zone, typically about 6 to 6.5 millimeters in diameter, with a transition zone tapering out to roughly 8.5 to 9 millimeters that blends the treated and untreated cornea more gradually. The size of that zone does not change with prescription; what changes is the amount of treatment delivered within it. In daylight, your pupil constricts to roughly 3 millimeters, which keeps all the light entering your eye within the perfectly treated central portion of the optical zone. The result is sharp vision.

At night, your pupil dilates. In dim light it commonly opens to 6 millimeters or more. In some patients, especially younger patients and those with naturally larger pupils, the pupil can dilate to 7 or 8 millimeters.

When the pupil dilates beyond the central, fully treated area of the optical zone, some of the light entering the eye passes through the peripheral cornea, which has a different curvature than the central treatment area. The transition between treated and untreated cornea creates optical irregularity, and the light scatters as it reaches the retina. The patient experiences this as halos around oncoming headlights, starbursts around streetlights, and a hazy glare that reduces contrast sensitivity in low-light conditions.

The higher the prescription, the more aggressive the treatment inside the optical zone, and the more pronounced the transition between treated and untreated cornea becomes. At -3.00 D, this transition is gentle. At -6.00 D, it is more noticeable. At -10.00 D, the difference in curvature between treated and untreated cornea is dramatic, and patients with large pupils frequently experience significant night vision symptoms that do not resolve over time.

Modern LASIK platforms like WaveLight® Plus with INNOVEYES SightMap™ have meaningfully improved this with topography-guided ablation profiles, but the underlying physics still apply.

Why EVO ICL for High Prescriptions Outperforms LASIK

EVO ICL works by adding a corrective lens inside the eye rather than reshaping the cornea. This single architectural difference eliminates both of the constraints that limit LASIK at high prescriptions.

No tissue is removed. Corneal thickness is not a factor in candidacy. A patient with a 500-micron cornea has exactly the same anatomical access to EVO ICL as a patient with a 600-micron cornea. The PTA calculation simply does not apply. This is also why thin corneas, which often accompany high prescriptions, are not a barrier to EVO ICL.

The optical correction sits inside the eye, behind the iris. Because the EVO ICL is positioned just behind the iris and just in front of the natural lens, the light entering the eye passes through the corrective lens regardless of pupil size. There is no transition between a treated and untreated zone, because there is no treated zone on the cornea at all. The optical correction is uniform across the entire pupil aperture, in daylight and at night, at all prescriptions from -3.00 D up to -20.00 D.

This is why patients with prescriptions in the -8.00 D to -20.00 D range consistently report excellent night vision after EVO ICL, with halos and starbursts that are far less common than after high-prescription LASIK. The architecture of the procedure eliminates the night vision tradeoff at the source.

Size Matters for EVO ICL

One detail many patients don’t realize is that the EVO ICL is not a one-size-fits-all device. The lens must be sized precisely to the anatomy of each individual eye. If the lens is too small, it can shift or rotate inside the eye, which compromises the optical correction and can require a second procedure to replace it with a different size. If the lens is too large, it can press against surrounding structures, raise eye pressure, or accelerate cataract formation. Getting the size right is one of the most consequential decisions in EVO ICL surgery, and the level of precision varies significantly between practices.

The Benefit of Reversibility: A Real-World Example

A patient I implanted with an ICL in 2006 had a prescription of approximately -9.50 D in one eye and -9.25 D in the other. Her corneas were healthy but did not have the thickness to support LASIK at that prescription. Twenty years later, she returned to my office to have refractive lens exchange after the ICL had served her perfectly across two decades. You can read the full case study here, including what we observed when we removed the ICL after 20 years.

That patient’s story is a useful reminder that the EVO ICL is not just a workaround for patients who cannot have LASIK. For patients with high prescriptions, the procedure is often the genuinely better long-term choice, both for the immediate visual outcome and for the future flexibility that reversibility preserves.

What Your Consultation Will Cover

If you have been told you have too high a prescription for LASIK, the right next step is a thorough evaluation by a surgeon who is experienced with both LASIK and EVO ICL, and who can speak honestly about which is right for your specific eyes.

At your evaluation in my office, I will personally measure:

• Your exact glasses prescription, including the strength of any astigmatism
• Corneal thickness and topography
• Anterior chamber depth and angle anatomy
• Endothelial cell density
• Axial length (important for determining retinal detachment risk in long, highly myopic eyes)
• UBM AI™ imaging of the structures behind the iris where the ICL will sit, combined with ICLguru® for precision lens sizing
• Pupil size in both light and dark conditions

The combination of these measurements determines whether LASIK, EVO ICL, or in some cases refractive lens exchange is the right procedure for you. Most patients with high prescriptions leave my office with a clear answer and a clear plan.

The Bottom Line

LASIK is an excellent procedure for patients whose corneas can safely support it. For patients with high prescriptions, the math of safe tissue removal and the physics of night vision both make LASIK a less appropriate choice as the diopters climb. EVO ICL was designed for exactly these eyes, and in my experience it consistently delivers the vision that LASIK cannot safely produce at the high end of the prescription range.

For a comprehensive overview of how EVO ICL compares to LASIK across all candidacy factors, see our complete EVO ICL pillar guide. For a direct side-by-side comparison of the two procedures across every candidacy factor, see EVO ICL vs. LASIK.

If you would like to know whether EVO ICL is the right choice for your eyes, I would be glad to evaluate you personally. Every consultation at Feinerman Vision is conducted by me, not by a delegated team. You can request a consultation at FeinermanVision.com or by calling (949) 631-4780.